To hear about similar clinical trials, please enter your email below
Trial Title:
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
NCT ID:
NCT06547476
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Tislelizumab
Immune Checkpoint Inhibitors
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
Description:
Tucidinostat (chidamide)，30mg, po., biw PD-1 inhibitor (tislelizumab), 200mg, ivgtt. d1,
q3w anlotinib, 12mg, po., d1-14, q3w
Arm group label:
Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), Anlotinib
Summary:
This Phase II study was designed to assess the efficacy and safety of the combination of
PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib
in advanced breast cancer.
Participants must have HER2-low and PD-L1 positive （CPS≥1）breast cancer that has been
treated before.
Participants' cancer:
Cannot be removed by an operation Has spread to other parts of the body
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Has pathologically documented breast cancer that:
- Is unresectable or metastatic
- Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
- Is HR-positive
- Has progressed on, and would no longer benefit from, endocrine therapy
- Has been treated with 0 to 1 prior lines of chemotherapy in the recurrent or
metastatic setting
- Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing
(per American Society of Clinical Oncology-College of American Pathologists
[ASCO-CAP] guidelines)
- PD-L1 positive （CPS≥1）
2. Has documented radiologic progression (during or after most recent treatment)
3. Has adequate archival tumor samples available or is wiling to provide fresh biopsies
prior to randomization for:
- assessment of HER2 status
- assessment of post-treatment status
4. Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors
1.1
5. Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood
clotting functions
6. Male and female participants of reproductive/childbearing potential, agrees to
follow instructions for method(s) of contraception and agrees to avoid preserving
ova or sperm for at least 4.5 months after treatment (or longer, per locally
approved labels)
Exclusion Criteria:
1. Allergies to any monoclonal antibody or tucidinostat preparation have been known,
and hypersensitivity reactions of more than 3 levels have occurred
2. Previously received histone deacetylase inhibitors,or immune checkpoint inhibitor,
or angiogenesis inhibitors.
3. Subjects with any active, known or suspected autoimmune disease or history of
autoimmune disease.
4. Known active CNS metastases and/or carcinomatous meningitis.
5. Received a live vaccine within 4 weeks of the first dose of study medication.
6. Major surgery received or severe traumatic injury, fracture, or ulcer occurred
within 4 weeks of the first dose of study medication.
7. Pregnant or lactating female.
8. Uncontrolled clinically significant systemic diseases, including active infection,
unstable angina, angina occurred within 3 months,≥ NYHA II congestive heart failure,
myocardial infarction occurred within 6 months, severe arrhythmia, liver, kidney, or
metabolic disease.
9. Participate in other clinical trials currently or within 4 weeks prior to
enrollment.
Gender:
Female
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Start date:
September 1, 2024
Completion date:
December 31, 2026
Lead sponsor:
Agency:
Guangdong Provincial People's Hospital
Agency class:
Other
Source:
Guangdong Provincial People's Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06547476
